Gilead Sciences to Buy CymaBay Therapeutics for $4.3 Billion
Gilead Sciences has agreed to buy CymaBay Therapeutics for $4.3 billion in a deal that expands Gilead's liver portfolio.
Permian Rivals Reach Deal to Create $50 Billion Oil-and-Gas Behemoth
Diamondback Energy and Autry Stephens's Endeavor announce merger as torrid dealmaking continues in the oil patch.
Residential Solar Confronts a Critical Year
High rates and less-generous subsidies have pushed some rooftop solar companies into bankruptcy, and even survivors will have an uphill battle.
Videogame Industry Banks on Distant Coming Attractions
New Switch console and 'Grand Theft Auto VI' are on the horizon, but big game publishers Electronic Arts and Take-Two are expected to see only modest growth this year.
JB Hi-Fi Half-Year Net Profit Falls, Cuts Dividend
Australian electronics retailer JB Hi-Fi said its half-year net profit fell by 20%, as consumers pulled back on discretionary spending amid elevated inflation.
Aurizon CEO Says Buyback May be Possible as Outlook for Returns Improves
Australian rail-freight operator Aurizon Holdings may consider buying back shares, its chief executive said, after flagging a potential increase to shareholder returns next fiscal year.
Why Three Media Giants Made a Hail Mary Bet on Sports Streaming
Disney, Fox and Warner's venture to bundle live sports content-the latest hit to traditional cable packages-needs to cover high costs and keep leagues on board.
Elon Musk Must Testify in SEC's Twitter Inquiry
The federal court ruled that Musk's testimony is "relevant and material to the SEC's investigation" and not, as Musk claimed, "unduly burdensome."
Your Medicare Plan Might Not Include as Many Freebies Next Year
Insurers are likely to favor margins over growth, meaning benefits such as gym memberships might go.
The Priciest Shareholder Fight Ever Is Headed to Disney's Boardroom
More than $70 million could be spent in bid to win everyday investors' votes.
(END) Dow Jones Newswires